Viking Therapeutics, Inc. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Viking Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2022-12-31 was $0.00.
- Viking Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2022-09-30 was $0.00.
- Viking Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2022-06-30 was $1.67M.
- Viking Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2022-03-31 was $5.12M.
- Viking Therapeutics, Inc. treasury stock, value, acquired, cost method for fiscal 2022 was $6.79M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $6.79M 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | |
| 2022-06-30 | $1.67M 10-Q · filed 2023-07-26 | |
| 2022-03-31 | $5.12M 10-Q · filed 2023-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |